Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012, Article ID 302495, 10 pages
http://dx.doi.org/10.1155/2012/302495
Research Article

PPAR 𝜶 -Independent Arterial Smooth Muscle Relaxant Effects of PPAR 𝜶 Agonists

1Muscle Biology Research Group (MUBIG), Basic Medical Science Department, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
2Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USA

Received 15 June 2012; Accepted 26 July 2012

Academic Editor: Richard P. Phipps

Copyright © 2012 Neerupma Silswal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. H. Van Raalte, M. Li, P. H. Pritchard, and K. M. Wasan, “Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future,” Pharmaceutical Research, vol. 21, no. 9, pp. 1531–1538, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Issemann and S. Green, “Cloning of novel members of the steroid hormone receptor superfamily,” Journal of Steroid Biochemistry and Molecular Biology, vol. 40, no. 1–3, pp. 263–269, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. S. S. T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the α isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995. View at Google Scholar · View at Scopus
  6. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Google Scholar · View at Scopus
  9. M. Gottlicher, E. Widmark, Q. Li, and J. A. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Yu, W. Bayona, C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated receptors by eicosanoids,” The Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARα-leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. F. J. Gonzalez, J. M. Peters, and R. C. Cattley, “Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor,” Journal of the National Cancer Institute, vol. 90, no. 22, pp. 1702–1709, 1998. View at Google Scholar · View at Scopus
  14. T. Lemberger, R. Saladin, M. Vázquez et al., “Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm,” The Journal of Biological Chemistry, vol. 271, no. 3, pp. 1764–1769, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Lemberger, B. Staels, R. Saladin, B. Desvergne, J. Auwerx, and W. Wahli, “Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids,” The Journal of Biological Chemistry, vol. 269, no. 40, pp. 24527–24530, 1994. View at Google Scholar · View at Scopus
  16. H. B. Rubins, S. J. Robins, and D. Collins, “The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol,” American Journal of Cardiology, vol. 78, no. 5, pp. 572–575, 1996. View at Google Scholar · View at Scopus
  17. H. B. Rubins, S. J. Robins, D. Collins et al., “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol,” The New England Journal of Medicine, vol. 341, no. 6, pp. 410–418, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. H. B. Rubins, S. J. Robins, D. Collins et al., “Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT),” Archives of Internal Medicine, vol. 162, no. 22, pp. 2597–2604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. H. Frick, O. Elo, K. Haapa et al., “Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease,” The New England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987. View at Google Scholar · View at Scopus
  20. V. Manninen, M. O. Elo, M. H. Frick et al., “Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study,” Journal of the American Medical Association, vol. 260, no. 5, pp. 641–651, 1988. View at Google Scholar · View at Scopus
  21. A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. G. Robinson, “Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE,” Current Atherosclerosis Reports, vol. 9, no. 1, pp. 64–71, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. C. Calkin, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen, “Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation,” Diabetologia, vol. 49, no. 4, pp. 766–774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Collino, M. Aragno, R. Mastrocola et al., “Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643,” Free Radical Biology and Medicine, vol. 41, no. 4, pp. 579–589, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Okayasu, A. Tomizawa, K. Suzuki, K. I. Manaka, and Y. Hattori, “PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation,” Life Sciences, vol. 82, no. 15-16, pp. 884–891, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Wang, Y. Wang, Q. Yang et al., “Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells,” Atherosclerosis, vol. 187, no. 2, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Li, C. J. Binder, A. Gutierrez et al., “Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ,” Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Tabernero, K. Schoonjans, L. Jesel, I. Carpusca, J. Auwerx, and R. Andriantsitohaina, “Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation,” BMC Pharmacology, vol. 2, no. 1, article 10, 2002. View at Google Scholar · View at Scopus
  29. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar · View at Scopus
  30. K. Nakagawa, V. R. Holla, Y. Wei et al., “Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1696–1702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Suardíaz, G. Estivill-Torrús, C. Goicoechea, A. Bilbao, and F. Rodríguez de Fonseca, “Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain,” Pain, vol. 133, no. 1–3, pp. 99–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. González-Yanes, A. Serrano, F. J. Bermúdez-Silva et al., “Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways,” American Journal of Physiology, vol. 289, no. 5, pp. E923–E929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Takeda, A. Matsuzawa, H. Nishitoh et al., “Involvement of ASK1 in Ca2+—induced p38 MAP kinase activation,” EMBO Reports, vol. 5, no. 2, pp. 161–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. O. S. Gardner, B. J. Dewar, H. S. Earp, J. M. Samet, and L. M. Graves, “Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46261–46269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. O. S. Gardner, B. J. Dewar, and L. M. Graves, “Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling,” Molecular Pharmacology, vol. 68, no. 4, pp. 933–941, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. L. E. Phelps and J. D. Peuler, “Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil,” Journal of Smooth Muscle Research, vol. 46, no. 3, pp. 125–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Liu, J. Yang, X. Huang et al., “Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs,” Vascular Pharmacology, vol. 56, no. 3-4, pp. 168–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. J. Andresen, N. I. Shafi, W. Durante, and R. M. Bryan, “Effects of carbon monoxide and heme oxygenase inhibitors in cerebral vessels of rats and mice,” American Journal of Physiology, vol. 291, no. 1, pp. H223–H230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Bryan Jr., J. You, S. C. Phillips et al., “Evidence for two-pore domain potassium channels in rat cerebral arteries,” American Journal of Physiology, vol. 291, no. 2, pp. H770–H780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. N. K. Parelkar, N. Silswal, K. Jansen, J. Vaughn, R. M. Bryan, and J. Andresen, “2,2,2-Trichloroethanol activates a nonclassical potassium channel in cerebrovascular smooth muscle and dilates the middle cerebral artery,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 3, pp. 803–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Silswa, N. K. Parelkar, M. J. Wacker, M. Brotto, and J. Andresen, “Phosphatidylinositol 3,5-bisphosphate increases intracellular free Ca2+ in arterial smooth muscle cells and elicits vasocontraction,” American Journal of Physiology, vol. 300, no. 6, pp. H2016–H2026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. P. J. Brown, L. W. Stuart, K. P. Hurley et al., “Identification of a subtype selective human PPARα agonist through parallel-array synthesis,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 9, pp. 1225–1227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Madej, B. Okopien, J. Kowalski et al., “Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb,” International Journal of Clinical Pharmacology and Therapeutics, vol. 36, no. 6, pp. 345–349, 1998. View at Google Scholar · View at Scopus
  44. A. Berger and M. A. Roberts, Unraveling Lipid Metabolism with Microarrays, Marcel Dekker, New York, NY, USA, 2005.
  45. A. B. Ropero, P. Juan-Picó, A. Rafacho et al., “Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPARα ligands in mouse pancreatic islets of Langerhans,” Journal of Endocrinology, vol. 200, no. 2, pp. 127–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Jiménez, M. Sánchez, M. J. Zarzuelo et al., “Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor β agonists via the phosphatidyl-inositol-3 kinase-Akt pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 2, pp. 554–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Y. Ali, S. J. Davidson, L. A. Moraes et al., “Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ,” FASEB Journal, vol. 20, no. 2, pp. 326–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps, “Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes,” Blood, vol. 104, no. 5, pp. 1361–1368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Kubo, Y. Nakaya, S. Matsuoka, K. Saito, and Y. Kuroda, “Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells,” Circulation Research, vol. 74, no. 3, pp. 471–476, 1994. View at Google Scholar · View at Scopus
  50. S. Chrissobolis and C. G. Sobey, “Inhibitory effects of protein kinase C on inwardly rectifying K+- and ATP-sensitive K+ channel-mediated responses of the basilar artery,” Stroke, vol. 33, no. 6, pp. 1692–1697, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Goyal, A. Mittal, N. Chu, L. Shi, L. Zhang, and L. D. Longo, “Maturation and the role of PKC-mediated contractility in ovine cerebral arteries,” American Journal of Physiology, vol. 297, no. 6, pp. H2242–H2252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Lagaud, N. Gaudreault, E. D. W. Moore, C. Van Breemen, and I. Laher, “Pressure-dependent myogenic constriction of cerebral arteries occurs independently of voltage-dependent activation,” American Journal of Physiology, vol. 283, no. 6, pp. H2187–H2195, 2002. View at Google Scholar · View at Scopus
  53. M. L. Pucci, X. Tong, K. B. Miller, H. Guan, and A. Nasjletti, “Calcium- and protein kinase C-dependent basal tone in the aorta of hypertensive rats,” Hypertension, vol. 25, no. 4, pp. 752–757, 1995. View at Google Scholar · View at Scopus
  54. B. Agrawal, J. Kopecký, B. Kränzlin, P. Rohmeiss, J. Pill, and N. Gretz, “Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats,” Nephrology Dialysis Transplantation, vol. 13, no. 2, pp. 333–339, 1998. View at Google Scholar · View at Scopus
  55. G. Assmann and H. Schulte, “The Prospective Cardiovascular Munster study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension,” American Journal of Cardiology, vol. 59, no. 14, pp. 9G–17G, 1987. View at Google Scholar · View at Scopus
  56. G. Kojda and B. Mayer, Therapeutic Importance of Nitrovasodilators Nitric Oxide, Springer, Berlin, Germany, 2000.